FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Luu Brendan (Last) (First) (Middle) C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET						Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC ENTA] 3. Date of Earliest Transaction (Month/Day/Year) 11/19/2021								Relationship of Reporting Person(s) to Issuer leck all applicable) Director 10% Owner X Officer (give title Other (specify below) Sr. VP, Business Dev.				
(Street) WATERTOWN MA 02472 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) ative Securities Acquired, Disposed of, or Benefic							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
1. Title of Security (Instr. 3) 2. Transa Date				. Transactio	action 2A. Deemed Execution Date,		3. Transac	ction	4. Securities Acquired (A) Disposed Of (D) (Instr. 3,			or 5. Amoun		nt of 6. O s Forr ally (D) o		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
Common Stock				11/19/20	9/2021		Code A ⁽¹⁾	v	Amount 6,800	(A) or (D) Pr		e \$0	Transact (Instr. 3 a	esported ansaction(s) estr. 3 and 4)		D	(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	action (Instr.	of E		s. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		1	3. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisabl		expiration Date	Title	Amou or Numb of Share	er					
Stock Option (right to buy)	\$75.33	11/19/2021		A		28,400		(2)	1	1/19/2031	Common Stock	28,4	00	\$0	28,400	0	D	

Explanation of Responses:

- 1. Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.
- 2. Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

/s/ Nat<u>haniel S. Gardiner as</u>

11/23/2021

attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.